Company
Lin BioScience, Inc.
Headquarters: Taipei, Taiwan
CEO: Dr. Yuxin Lin M.B.A., Ph.D.
Market Cap
TW$11.20 Billion
TWD as of Jan. 1, 2025
US$341.4 Million
Lin BioScience, Inc. Categories
Taiwan Healthcare BiotechnologyTaiwan Healthcare Taiwan Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (AMD) and stargardt diseases; LBS-007, a natural non-ATP CDC7 inhibitor for the treatment of cancers; LBS-002, an anti-tubulin to treat primary and metastatic brain tumors; and LBS-009, an oral therapy for the treatment of non-alcoholic fatty liver disease and type 2 diabetes. The company is headquartered in Taipei City, Taiwan.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Stocks & Indices
Lin BioScience, Inc. has the following listings and related stock indices.
Stock: TWSE: 6696 wb_incandescent
Stock: MYX: 5789 wb_incandescent